KRRO VS ITOS Stock Comparison

Performance

KRRO
100/100

KRRO returned 192.66% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

ITOS
10/100

ITOS returned -55.33% in the last 12 months. Based on SPY's performance of 476.36%, its performance is below average giving it a score of 10 of 100.

Earnings

KRRO
100/100

KRRO has missed earnings 0 times in the last 20 quarters.

ITOS
10/100

ITOS has missed earnings 5 times in the last 20 quarters.

Volatility

KRRO
100/100

KRRO has had a higher than average amount of volatility over the last 12 months giving it a score of 100 of 100.

ITOS
40/100

ITOS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

Sentiment

KRRO

"Sentiment" not found for KRRO

ITOS
72/100

ITOS had a bullish sentiment score of 71.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 2.67 comments, and 4.00 likes per day.

Technicals

KRRO

"Technicals" not found for KRRO

ITOS
14/100

ITOS receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Profit

KRRO

"Profit" not found for KRRO

ITOS
31/100

Out of the last 19 quarters, ITOS has had 6 profitable quarters and has increased their profits year over year on 4 of them.

All score calculations are broken down here to help you make more informed investing decisions

Korro Bio, Inc. Common Stock Summary

Nasdaq / KRRO

Healthcare

Biotechnology

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

iTeos Therapeutics, Inc. Common Stock Summary

Nasdaq / ITOS

Healthcare

Biotechnology

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Power up your portfolio